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Abstract
Objective—To determine if SMAD4 expression is associated with recurrence pattern after 
resection for pancreatic ductal adenocarcinoma (PDA)
Introduction—SMAD4 expression status has been reported to be associated with patterns of 
failure in PDA, but studies have not examined recurrence patterns after resection.
Methods—A tissue microarray was constructed including 127 patients with resected PDA and 
either short (<12 months) or long (>30 months) survival. SMAD4 expression was evaluated by 
immunohistochemistry and categorized as present or lost in tumor cells. Conventional pathologic 
features (lymph node metastases, positive resection margin, poor grade, tumor size) were 
recorded, and disease-specific outcomes (e.g. recurrence pattern and early cancer-specific 
mortality) determined.
Results—Loss of SMAD4 expression in pancreatic adenocarcinoma was identified in 40 of 127 
patients (32 %). SMAD4 loss occurred in 27% of patients who experienced isolated local 
recurrence, 33% of patients with a distant recurrence, 33% of patients who recurred locally and at 
distant sites, and 25% of patients who were without evidence of recurrence (Fisher's exact, p=0.9). 
In a multivariate analysis, the presence of regional lymph node metastases was the only factor 
associated with the development of distant metastases (odds ratio, OR=4.7, p=0.02). SMAD4 was 
neither associated with recurrence pattern (OR=0.9, p=0.9), nor early death (OR=0.5, p=0.15).
Conclusion—Primary tumor SMAD4 expression status was not a predictor of recurrence pattern 
in a large cohort of patients with resected PDA.
Corresponding author: Peter J. Allen, MSKCC. Department of Surgery Hepatopancreatobiliary Service 444 E 68th St Mailbox 328 
New York, NY 10065 Fax: (212) 717-3645 Phone: (212) 639-5132.
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Introduction
The management approach for pancreatic ductal adenocarcinoma has not changed 
significantly over the past two decades, aside from more frequent use of neoadjuvant 
treatment at some centers[1] and the use of the multi-drug regimen FOLFIRINOX (5-
fluorouracil, leucovorin, irinotecan, and oxaliplatin) in good performance status patients 
with advanced disease [2]. Most patients are treated similarly using an empiric gemcitabine-
based approach, despite the fact that pancreatic adenocarcinoma is a heterogeneous disease 
with significant molecular differences between tumors [3]. In the modern era of molecular 
profiling, there has been a push to identify molecular signatures that could be used to predict 
tumor biology, and perhaps tailor treatment [4-8].
In this context, two intriguing studies have recently been published which suggest that the 
SMAD4 expression pattern in pancreatic cancer is associated with disease distribution and 
eventual pattern of failure [9, 10]. One study analyzed SMAD4 expression patterns in 
pancreatic cancer in autopsies [10], and a second study focused on patients with locally 
advanced disease [9]. The studies reached similar conclusions in two distinct patient 
populations- that SMAD4 protein expression was associated with a locally predominant 
progression pattern (with treatment implications for local therapies such as radiation) while 
loss of SMAD4 was associated with distant metastases (with adjuvant radiation less likely to 
impact outcome). Validation in patients with resectable pancreatic cancer would support a 
treatment paradigm based on SMAD4 expression status, where chemoradiation would be 
favored in patients harboring tumors with retained SMAD4 expression. On the other hand, 
patients with absent SMAD4 expression would be reasonably spared the toxic effects of 
such treatment. In this study, we assessed the utility of SMAD4 expression status as a 
biomarker of recurrence pattern in a large cohort of patients with resectable pancreatic 
cancer.
Methods
Patients
This study was approved by the Memorial Sloan-Kettering Cancer Center (MSKCC) 
institution review board. Patients underwent a pancreaticoduodenectomy or a distal 
pancreatectomy for ductal adenocarcinoma at MSKCC after the year 2000. Patients were 
selected based on survival, and included if they suffered a cancer-specific death within 1 
year of resection (short survivors) or survived at least 30 months (long survivors). The TMA 
was constructed as part of a separate study of prognostic factors (manuscript in submission). 
As described elsewhere, survival cutoffs were selected to achieve a time gap between study 
groups (>18 months) that adequately distinguished aggressive and less aggressive tumor 
biology, and still yielded sample sizes with sufficient power for statistical analyses. In the 
present study, the study design which included dichotomous groups based on survival 
enabled comparisons of SMAD4 expression at two ends of the biological spectrum; the 
more aggressive variety has a biological phenotype that more closely approximates the 
phenotypes of PDAs included in the two aforementioned studies of SMAD4 in advanced 
pancreatic cancer [9, 10].
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Clinicopathologic Information
Clinicopathologic data were extracted from the prospectively maintained MSKCC 
Pancreatic Surgery Database and from review of electronic medical records. Collected 
pathologic variables included resection margin status, lymph node status, tumor size, and 
histologic grade. Clinical information included recurrence pattern and the use of adjuvant 
chemotherapy or radiation. The recurrence pattern was determined through careful 
examination of medical records and follow-up imaging. Both synchronous and 
metachronous sites of recurrence were recorded. A local recurrence was defined as a 
retroperitoneal recurrence that occurred either in the resection bed or in the retroperitoneal 
lymph nodes. A distant recurrence was defined as recurrence at any other site, such as in the 
peritoneum, liver, lungs, or other solid organ. For patients who had not reached the endpoint 
of death, the pattern of failure at the time of the last patient encounter was recorded.
Tissue Preparation
A tissue microarray (TMA) was constructed from tissue cores obtained from formalin-fixed, 
paraffin-embedded tissue blocks in 151 patient samples. A single representative block was 
selected from each patient, and areas with the highest tumor density on a corresponding H & 
E stained section were marked under the microscope. TMA's were then constructed on an 
automated tissue array machine (ATA-27, Beecher Instruments, Silver Spring, MD). 
Triplicate cores of 0.6 mm in diameter were punched from each block and transferred to a 
virgin TMA block. Cores were placed on the block in no particular order so that 
immunohistochemical review of stained TMA slides could be performed in an unbiased 
fashion. Four micron thick sections were prepared from the TMA blocks for H & E stains 
and used for SMAD4 immunohistochemistry.
Immunohistochemical Analysis
Immunohistochemical stains were performed using a standard streptavidin-biotinperoxidase 
procedure. Thin 4 μm paraffin sections were deparaffinized and hydrated with distilled 
water. Heat-induced epitope retrieval with citric acid buffer (pH 6, 30 minutes, at 97°C) was 
performed with a steamer. Slides were cooled to 60°C and washed in running water for 2 
minutes, and transferred to PBS buffer. A primary antibody against SMAD4 (1:800, Santa 
Cruz Bio, Santa Cruz, CA) was applied overnight at 4°C. The slides were washed with PBS, 
followed by a secondary antibody (1:500, biotinylated anti-mouse, Vector Labs, 
Burlingame, CA) for 60 minutes at room temperature. After additional washing, the slides 
were incubated for 60 minutes with streptavidin, washed, and developed with DAB for 5 
minutes. The slides were washed and counterstained with Harris hematoxylin.
Immunohistochemical review was performed by a senior pancreatic pathologist (L.H.T.). A 
second pathologist scored the TMAs to test for inter-rater reliability (W.L.). Pancreatic 
ductal adenocarcinomas were considered to have absent SMAD4 expression if neoplastic 
cells lacked immunohistochemical labeling but non-neoplastic cells (e.g. stromal cells) 
reacted positively as an internal control [9, 10]. Any convincing labeling was considered as 
positive for individual cores, and the predominant SMAD4 expression pattern in each 
triplicate set was recorded for analysis. Representative cores labeled with an antibody to 
SMAD4 are provided in Figure 1.
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Statistical Analysis
The analysis was performed using Intercooled Stata 8.2. Categorical variables were tested 
by the Fisher's exact test in the univariate analysis, and with logistic regression in the 
multivariate analysis. Inter-rater agreement of SMAD4 immunohistochemistry was assessed 
with the kappa statistic, and interpreted according to the following scale: κ<0 shows poor 
agreement, 0 to 0.20 shows slight agreement, 0.21 to 0.40 shows fair agreement, 0.41 to 0.60 
shows moderate agreement, 0.61-0.80 shows substantial agreement, and >0.80 shows almost 
perfect agreement [11]. All statistics were two-tailed with a p value<0.05 indicating 
statistical significance.
Results
The TMA included 151 different patient samples. There was insufficient neoplastic 
cellularity for proper assessment of SMAD4 expression in 9 sample sets and the recurrence 
pattern could not be determined using available follow-up documentation in 15 patients. The 
final analysis therefore included 127 patients, including 110 right sided lesions and 17 left 
sided lesions. The specimens were analyzed in aggregate, as well as in subgroups stratified 
by survival after resection (i.e. short and long survivors). A total of 56 patients had a short 
cancer-specific survival after resection (survival<12 months) and 71 patients had a relatively 
long survival (survival>30 months). The endpoint of death occurred in 112 of the 127 
patients (88%). Median follow-up in living patients was 48 months (range 31-108 months).
Patients were grouped into one of four categories based on their recurrence pattern. The 
distribution of patients by recurrence pattern is provided in Table 1; the data are presented 
for the total cohort, as well as each survival group. Recurrence patterns for the total cohort 
were as follows: local recurrence only (n=15, 12%), distant recurrence only (n=42, 33%), 
both local and distant recurrence (n=58, 46%), and no recurrence (n=12, 9%). The majority 
of patients failed outside of the retroperitoneum (n=100, 79%). Out of these patients, just 
over half (n=58, 58%) developed a local recurrence in addition to a distant metastasis. 
Virtually all of the patients who recurred locally in the retroperitoneum without distant 
failure (i.e. local recurrence only) had tumors with a relatively favorable biology (13 out of 
15 patients were in the long survival group). Patients with distant recurrences are more or 
less equally divided between the short and long survivor groups, regardless of whether or 
not a local recurrence was also present.
With regards to specific organ sites of recurrence, 73 of 127 patients (57%) had a 
retroperitoneal recurrence, 66 (52%) recurred in the liver, 44 (35%) elsewhere in the 
peritoneum, and 19 (15%) in the lung. Less common sites of metastases included the brain, 
bone, spine, soft tissue, adrenal gland, salivary gland, and tongue (Figure 2). Roughly half of 
the patients were noted to have recurred at multiple sites (n=62, 49%), and twelve patients 
(9%) had not experienced disease recurrence. At last follow-up, 9 of the 12 patients without 
disease remained alive with a median follow up of 60 months (range, 31-108 months). Of 
note, patients who died an early cancer-specific death recurred more frequently in the liver 
than patients with a prolonged survival (75% vs. 34%, p<0.0001). In contrast, lung 
metastases were more common in long-term survivors (21% vs. 7%, p=0.04).
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Next, we examined whether or not an association existed between SMAD4 expression and 
the pattern of failure (Table 2). Loss of SMAD4 expression in the tumor was observed in 
32% of the total cohort, and ranged between 25% and 33% for each recurrence category 
(p=0.9). When the subgroup of patients with the most biologically aggressive tumors was 
examined (the short survivors share a similar aggressive phenotype with many patients in 
prior studies of SMAD4 and recurrence with advanced PDA), no difference amongst the 
recurrence patterns was observed (p=1.0, data not shown). Additionally, we analyzed the 
data according to anatomic or organ-specific site of metastasis (Figure 2). Since many 
patients recurred at multiple sites and therefore are included in multiple organ-specific 
subgroups, the data were not evaluated statistically. Loss of SMAD4 across the four most 
common metastatic sites were as follows: retroperitoneum, 32%; liver, 35%; peritoneum, 
32%; and lung, 32%. With regards to primary tumor location, loss of SMAD4 was observed 
in 30% of right sided lesions and 41% of left sided lesions (p=0.2).
A multivariate analysis was performed to evaluate SMAD4 as a predictor of recurrence 
pattern after adjusting for conventional pathologic features and adjuvant treatment data. 
Only patients with documented recurrences were included in the subgroup analysis, and 
patients without any evidence of disease (n=12) at the time of the study were excluded. For 
simplicity, patients with distant metastases (including those with ‘distant-only recurrence,’ 
and those with ‘distant and local recurrence’) were collapsed into a single category for the 
regression model and compared to patients with a local-only recurrence (Table 3). Adjuvant 
therapy did not play a role in recurrence patterns, and this was consistent when either 
chemotherapy or radiation was factored into the model. Similarly, SMAD4 did not have any 
predictive value. Regional lymph node metastases were significantly associated with distant 
metastases, while other conventional pathologic features were not. Table 4 details the lymph 
node status according to recurrence pattern. While lymph node metastases were absent in 
28% (36 of 127) of the total cohort, 60% (9 of 15 patients) of the patients in the local-only 
group were free of lymph node metastases (Fisher's exact= 0.04, Table 4).
SMAD4 has been implicated as a prognostic marker, and therefore we evaluated the 
biomarker's ability to distinguish short- and long-term survivors in the present cohort. Loss 
of SMAD4 was observed in 22 of 56 patients (39%) in the short survivor group, as 
compared to 18 of 71 patients (25%) in the long survivor group (p=0.12). A multivariate 
regression analysis was performed which included conventional pathologic features and 
adjuvant treatment. In this model SMAD4 did not reach statistical significance: SMAD4, 
odds ratio (OR)=0.5, p=0.15; positive lymph nodes, OR=4.5, p=0.005; positive resection 
margin, OR=1.5, p=0.5; poor differentiation, OR=2.8, p=0.02; tumor more than 3 cm, 
OR=2.2, p=0.07; adjuvant treatment, OR=0.3, p=0.02.
SMAD4 expression was scored by a second pathologist to test inter-rater reliability. There 
was substantial agreement between pathologists, with 83% agreement and κ=0.6114 
(p<0.0001). The entire analysis was repeated using scores from the second pathologist, and 
none of the findings changed (data not included).
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Discussion
SMAD4 is a tumor suppressor gene involved in TGFβ signaling [12], and is inactivated by 
homozygous deletions or somatic mutations in over 50% of sporadic pancreatic 
adenocarcinomas [13-15]. In this study, primary tumor specimens from a large number of 
patients (n=127) with resected ductal adenocarcinoma of the pancreas were examined for 
SMAD4 expression and analyzed with respect to pattern of failure. SMAD4 expression was 
absent in approximately 1/3 of pancreatic adenocarcinomas, regardless of the survival 
outcome, general pattern of failure, or the specific organ site of recurrence. We believe this 
is an important finding in the context of two recent studies which observed that intact 
SMAD4 expression was associated with a local recurrence, while absent SMAD4 expression 
was associated with distant metastases [9, 10]. While we cannot definitively account for the 
different conclusions from our study, the most likely explanation relates to differences in 
patient selection.
Iacobuzio et al. profiled the pattern of failure in 76 autopsies performed on patients who 
died from pancreatic adenocarcinoma [10]. Less than 1/3 of the patients presented with 
resectable disease (Stage I or II), while the remaining patients presented with stage III (24%) 
or stage IV (47%) disease. In addition, 10% of patients had rare variants of non-
conventional ductal (tubular) adenocarcinoma. The authors examined SMAD4 expression in 
tumors of 65 of the autopsy specimens, and observed loss of SMAD4 in 41 (63%) of the 
samples. Just 2 of 9 autopsies that exhibited a pattern of locally advanced pancreatic cancer 
without metastases had tumors with loss of SMAD4 (22%). However, 16 of 22 patients with 
numerous metastases had tumors that lacked SMAD4 expression (78%). SMAD4 expression 
status was then analyzed in individuals with intermediate phenotypes, but who had 
recurrence patterns that could nonetheless be classified as either locally destructive or 
locally confined. Again, a statistically significant association between the recurrence pattern 
and SMAD4 expression status was noted when all 65 individuals were analyzed together 
(p=0.007).
A recent phase two trial examining chemotherapy followed by chemoradiation in patients 
with locally unresectable pancreatic cancer included a biological correlative component that 
examined SMAD4 expression in cytologic samples and analyzed the findings with respect to 
disease pattern [9]. Out of 41 patients with available tissue, 15 (37%) recurred in a local 
predominant pattern, 14 (34%) with distant metastases, and 8 (20%) with an indeterminate 
pattern. Out of 15 patients with intact SMAD4 expression in their tumors, 11 (73%) of them 
progressed locally. On the other hand, 10 of the 14 (71%) patients with loss of SMAD4 in 
their tumors recurred predominantly at distant sites (p=0.016).
An important difference between the two aforementioned studies and the present one is that 
the entire cohort of patients in the current one underwent a pancreatic resection. In contrast, 
only 29% of patients included in the autopsy study and 10% in the study of locally advanced 
pancreatic cancer underwent resection. While resection is not curative in the majority of 
patients, the intervention usually renders patients free of gross disease at the primary site, 
and in doing so, can have a profound impact on the recurrence pattern of the cancer. It is 
also possible that the cancers examined from the present series have a slightly different 
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biologic behavior as a group, since they generally presented at an earlier stage (AJCC 7th 
Ed/TNM stages I and II) than the cancers included in the previous SMAD4 studies 
(generally stages III or IV). Other distinguishing qualities of the present series include the 
relatively large samples size, the use of surgical pathology (as opposed to cytology) in all 
cases, and the uniformity with respect to tumor type (all ductal adenocarcinoma). Taken 
together, we believe that the findings herein comprise the most accurate and applicable 
published dataset of SMAD4 expression in surgical patients with pancreatic 
adenocarcinoma.
While previous studies classified recurrence patterns according to whether or not the tumor 
was locally destructive or locally predominant, we felt that a more clinically relevant 
classification scheme should be based on whether or not the recurrence was localized in the 
retroperitoneum. While this classification difference is largely semantic, a retroperitoneal 
recurrence, either in the resection bed or in the regional lymph nodes, is a local one. The 
recurrence can be treated by radiation with minimal acute toxicity to the intestinal tract. On 
the contrary, the therapeutic window with radiation therapy may be smaller for locally 
destructive tumors in other sites in the abdomen, such as the small bowel mesentery. Along 
these lines, recurrences limited to the retroperitoneum may be reduced, in theory, by 
adjuvant radiation.
Pathologic features of the tumor and treatment were included in a multivariate model to 
determine if these key variables influenced the study findings. SMAD4 failed to predict 
recurrence pattern in the multivariate model. Similarly radiation, chemotherapy, resection 
margin status, histologic grade, and tumor size were not associated with the pattern of 
failure. However, the absence of lymph node metastases in the resection specimen was 
associated with a local-only recurrence, while lymph node metastases predicted systemic 
recurrence. Patients with lymph node metastases in fact had an adjusted odds ratio for a 
systemic recurrence more than five-fold greater than patients without lymph node spread. 
Based on these findings, oncologists who selectively recommend adjuvant chemoradiation 
for ductal adenocarcinoma of the pancreas according to tumor related characteristics should 
give particular consideration for cancers without lymph node metastases. On the other hand, 
due to the high rate of systemic recurrences, resected patients with lymph nodes metastases 
may be less likely to benefit from adjuvant radiation therapy. In the present study, 9 patients 
without lymph node metastases in their resection specimen had a local-only recurrence. Of 
these patients, 6 (66%) did not receive adjuvant radiation therapy and in retrospect, may 
have benefited from additional local treatment.
Controversy exists in the literature regarding SMAD4 as a prognostic marker, in addition to 
a marker of recurrence pattern. For instance, SMAD4 expression was determined by direct 
sequencing in 89 patients with resected pancreatic ductal adenocarcinoma and inactivation 
was associated with worse survival (14 vs. 12 months, p=0.006) [16]. Interestingly, an older 
report described a population of 129 patients with pancreatic ductal adenocarcinoma (51 
who underwent resections), in which loss of SMAD4 was associated with improved survival 
(9 vs. 6 months, p=0.009), resectability, and earlier stage [17]. The differences disappeared 
in a multivariate model adjusting for pathologic features. In the present study, there is a 
trend towards worse survival with loss of SMAD4, which did not reach statistical 
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significance. Additional findings in the multivariate analysis were consistent with our 
overall experience of more than 1000 PDAs; lymph node metastases and poor histologic 
grade were statistically significant predictors of survival, while resection margin was not 
[18]. The consistency between the larger dataset and the present study with regards to 
standard pathologic features provides reassurance that the smaller group is representative in 
at least this one very important aspect. The present data, combined with prior studies, 
suggest that loss of SMAD4 may be associated with unfavorable prognosis in pancreatic 
cancer, although the connection is not robust.
The present study has certain limitations based on the study design that deserve mention. In 
contrast to the autopsy study, the ability to determine recurrence clinically and from imaging 
is difficult. The absence of a detected recurrence, local or distant, does not confirm the 
absence of disease. Furthermore, patients were included from two ends of the survival 
spectrum, and therefore we are required to extrapolate these results for patients with 
intermediate survivals. Finally, treatment regimens were variable. However, this last point 
can be viewed as an important requirement for a reliable biomarker to gain widespread 
acceptance, as these data reflect real world treatment patterns.
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Figure 1. 
SMAD4 immunohistochemistry in representative cores of pancreatic ductal 
adenocarcinoma. Neoplastic epithelial cells lack SMAD4 expression in contrast to 
nonneoplastic stromal cells in a) and b). SMAD4 expression is observed in cancer cells as 
well as the non-neoplastic stromal cells in c) and d).
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Figure 2. 
Percentage of patients (total, n=127) who recurred at the indicated sites. NED, no evidence 
of disease.
Winter et al. Page 11
Ann Surg. Author manuscript; available in PMC 2015 May 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Winter et al. Page 12
Table 1
Recurrence pattern, stratified by tumor biology (n=127)
Short survival, <12 months, n=56 Long survival, >30 months, n=71 All patients, n=127
Local recurrence only 2 (4%) 13 (18%) 15 (12%)
Distant recurrence only 21 (38%) 21 (30%) 42 (33%)
Local and distant recurrence 33 (59%) 25 (35%) 58 (46%)
No recurrence 0 (0) 12 (17%) 12 (9%)
Percentages are with respect to the specified cohort (i.e. each column)
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Table 2
Recurrence pattern and SMAD4 expression status (n=127)
SMAD4 Loss SMAD4 Expression
Total 40 (31.5%) 87 (68.5%)
Local recurrence only 4 (27%) 11 (73%)
Distant recurrence only 14 (33%) 28 (67%)
Local and distant recurrence 19 (33%) 39 (67%)
No recurrence 3 (25%) 9 (75%)
Percentages are with respect to recurrence pattern (i.e. each row)
SMAD4 loss vs. SMAD4 expression, Fisher's exact, p=0.9
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Table 3
Multivariate regression model of recurrence pattern: predictors of distant metastases (n=115)
N (%) Odds Ratio P value
Adjuvant therapy 43 (39%) 1.2 0.8
SMAD4 37 (32%) 1.2 0.8
Positive lymph nodes 81 (70%) 6.0 0.001
Positive resection margin 16 (14%) 1.3 0.8
Poor differentiation 39 (34%) 1.1 0.9
Size > 3 cm 73(64%) 1.9 0.3
The results are consistent when adjuvant chemotherapy or radiation are substituted for adjuvant therapy. The regressions estimate the risk of distant 
metastases. Patients in the 'distant recurrence only' category are grouped with patients who had both 'local and distant recurrence.' Patients with no 
evidence of disease (n=12) were excluded from the regression model, as many will recur at some point in the future.
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Table 4
Recurrence by site and lymph node status (n=127)
Negative Lymph Nodes, n=36 Positive Lymph Nodes N=91
Local recurrence only 9 (60%) 6 (40%)
Distant recurrence only 9 (21%) 33 (79%)
Local and distant recurrence 16 (28%) 42 (72%)
No recurrence 2 (17) 10 (83%)
Percentages are with regards to recurrence pattern (i.e. each row) P=0.04
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